People paying privately for weight-loss drug Mounjaro in the UK face a rise in the cost of the treatment after manufacturer Eli Lilly said it was increasing the list price of the drug by as much as 170%.

Eli Lilly will raise the UK list price of its weight-loss treatment Mounjaro by up to 170%, it said on Thursday, amid a White House push to get drugmakers to raise medicine prices in Europe to allow for price cuts in the United States.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure.